Publications

Publication of research results is a pivotal requirement for a comprehensive improvement of treatment concepts. iOMEDICO supports the international guidelines for transparency and reporting of medical research results.

We regularly present our data at national and international conferences. Our publications are published in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and scientists of iOMEDICO.

TITEL
STUDIE
JAHR
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

C C Schimanski, S Kasper, S Hegewisch-Becker, J Schroeder, F Overkamp, F Kullmann, W O Bechstein, M Vöhringer, R Oellinger, F Lordick, V Heinemann, M Geissler, A Schulz-Abelius, B Linz, H Bernhard, M R Schoen, R Greil, V Smith-Machnow, I Schmidtmann, M H Moehler, 2019.

Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 3537-3537. DOI: 10.1200/JCO.2019.37.15_suppl.3537

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
LICC
2019
Twice weekly carfilzomib is an accepted treatment by patients with Multiple Myeloma who have received at least one prior therapy: Interim results if the CARO study.

W. Knauf; A. Ammon; J. Uhlig; M. Merling; H.-J. Hurtz; T. Riedt; H. Schulz; C. Vannier; N. Marschner; K. Potthoff; 2019.

HemaSphere. 3():646–647, JUN 2019 DOI: 10.1097/01.HS9.0000563904.96659.51 Issn Print: 2572-9241

Abstract
Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
CARO
2019
Lenalidomide in combination with dexamethasone as first-line therapy in transplant-ineligible patients with Multiple Myeloma: Interim Results of the observational study FIRST-NIS.

H. Nückel; H.-J. Hurtz; H. Schulz; M. Schulze; M. Koenigsmann; T. Dechow; M. Merling; L. Houet; C. Vannier; K. Potthoff; 2019.

HemaSphere. 3():263–264, JUN 2019 DOI: 10.1097/01.HS9.0000560764.61601.55 Issn Print: 2572-9241

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
FIRST-NIS
2019
Pertuzumab beim HER2-positiven metastasierten Mammakarzinom in der Routinebehandlung – Daten aus dem Tumorregister Mammakarzinom.

Overkamp, F; Frühauf, S; Fietz, T; Behringer, J; Kruggel, L; Wetzel, N; Marschner, N, 2019.

Senologie 2019; 16(02): 31 – 31 DOI: 10.1055/s-0039-1688031

Abstract
Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
TMK
2019
Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.

M Boegemann, J Bedke, M Schostak, C Hering-Schubert, M Welslau, J Schleicher, T Wolf, A Petzoldt, C Doehn, C Grüllich, V Grünwald, T Steiner, A Rogler, S Hanson, D Klein, T Medinger, PJ Goebell, 2019.

J Clin Oncol 2019 37:15_suppl, 4574-4574

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
PAZOREAL
2019
Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

A Welt, M K Welslau, D Lüftner, M Deryal, R Liersch, J Sahlmann, L Houet, C Vannier, N Marschner, K Potthoff, 2019.

Ann Oncol Volume 30, Issue Supplement_3, May 2019, mdz100.007, https://doi.org/10.1093/annonc/mdz100.007

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
INGE-B
2019
Patient-based prospective real-world data analysis shows that the duration of treatment interruptions with subsequent resumption of idelalisib therapy can vary from days to months.

Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., von Troostenburg, A., Ramroth, H., Abenhardt, W., Rummel, M., 2019.

HemaSphere 3 (PS1163), 528–529. https://doi.org/10.1097/01.HS9.0000562936.05518.43

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
IDELA
2019
VicTORia: A Randomised Phase II Study to Compare Vinorelbine in Combination with the MTOR Inhibitor Everolimus versus Vinorelbine Monotherapy for Second-Line Chemotherapy in Advanced HER2-Negative Breast Cancer.

Decker, T., Marschner, N., Muendlein, A., Welt, A., Hagen, V., Rauh, J., Schröder, H., Jaehnig, P., Potthoff, K., Lerchenmüller, C. 2019.

Breast Cancer Research and Treatment, 2019. https://doi.org/10.1007/s10549-019-05280-2.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
VICTORIA
2019
Survival after secondary liver resection in metastatic colorectal cancer. A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3)

Moehler, M., Folprecht, M, Heinemann, V., Holch, J., Maderer, A., Kasper, S., Hegewisch-Becker, S., Schröder, J., Overkamp, F., Kullmann, F., Bechstein, W., Vöhringer, M., Öllinger, R., Lordick, F., Geißler, M., Schulz-Abelius, A., Linz, B., Bernhard, H., Schmidtmann, I., Schimanski, C.

J Clin Oncol 37 (4_suppl)(571). doi:10.1200/JCO.2019.37.4_suppl.571

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: GI (ASCO) / Journal: Journal of Clinical Oncology
LICC
2019
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results

Schimanski, C., Kasper, S., Hegewisch-Becker, S., Schröder, J., Overkamp, F., Kullmann, F., Beckstein, W., Vöhringer, M., Öllinger, R., Lordick, F., Heinemann, V., Geißler, M., Schulz-Abelius, A., Linz, B., Bernhard, H., Schoen, M., Greil, R., Smith-Machnow, V., Schmidtmann, I., Moehler, M.

J Clin Oncol 37 (4_suppl)(480). doi:10.1200/JCO.2019.37.4_suppl.480

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: GI (ASCO) / Journal: Journal of Clinical Oncology
LICC
2019